RAPT Therapeutics, Inc. (RAPT) Covered Calls
There are no covered calls available for RAPT Therapeutics, Inc..
Born To Sell's covered call screener gives you full search capabilities so you can find stocks and ETFs that make good covered call candidates.
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | GAP covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | RCAT covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | APLD covered calls | |
| 4. | IBIT covered calls | 9. | FXI covered calls | 4. | ONDS covered calls | |
| 5. | SPY covered calls | 10. | KWEB covered calls | 5. | CTMX covered calls | |
Want more examples? RAMP Covered Calls | RARE Covered Calls
